Results · Apr-Jun 2026 · filed 8 Aug 2026
Akums Drugs and Pharmaceuticals Q1 FY27 results
StrongStrong: sales up 10% or more & profit up 20% or more on the same quarter last year, with a wider operating margin.
Sales grew 14% to ₹1,167 crore from ₹1,024 crore in Apr-Jun 2025.
Operating profit grew 35% to ₹175 crore, an operating margin of 15.0% (up 2.4 points from a year ago).
Net profit grew 56% to ₹101 crore from ₹64.7 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +1%, net profit +24%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 1,167 | 1,024 | +14% |
| Operating profit (EBITDA) | 174.7 | 129.0 | +35% |
| Operating margin | 15.0% | 12.6% | +2.4 pts |
| Net profit | 101.0 | 64.7 | +56% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Apr–Jun 2026 revenue grew 13.9% to ₹1,167 crore with EBITDA up 35.4% to ₹175 crore. CDMO segment led with 18.6% growth & double-digit volumes. Management expects CDMO volumes in high teens, API segment approaching profitability & Zambia orders starting Q3.
The last 7 quarters
Filings that week
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 10 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 10 Aug 2026Newspaper Publication
- 10 Aug 2026Monitoring Agency Report
- 8 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 8 Aug 2026Press Release
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.